Abstract
CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001; 14: 277–289.
Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev 2002; 190: 123–136.
Davis RS, Dennis Jr G, Kubagawa H, Cooper MD . Fc receptor homologs (FcRH1-5) extend the Fc receptor family. Curr Top Microbiol Immunol 2002; 266: 85–112.
Guselnikov SV, Ershova SA, Mechetina LV, Najakshin AM, Volkova OY, Alabyev BY et al. A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1. Immunogenetics 2002; 54: 87–95.
Mechetina LV, Najakshin AM, Volkova OY, Gueslnikov SV, Faizulin RZ, Alabyev BY et al. FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features. Eur J Immunol 2002; 32: 87–96.
Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R . IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood 2002; 99: 2662–2669.
Nakayama Y, Weissman SM, Bothwell AL . BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun 2001; 285: 830–837.
Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD . An extended family of Fc receptor relatives. Eur J Immunol 2005; 35: 674–680.
Davis RS, Wang YH, Kubagawa H, Cooper MD . Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 2001; 98: 9772–9777.
Davis RS, Stephan RP, Chen CC, Dennis Jr G, Cooper MD . Differential B cell expression of mouse Fc receptor homologs. Int Immunol 2004; 16: 1343–1353.
Ise T, Maeda H, Santora K, Xiang L, Kreitman RJ, Pastan I et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res 2005; 11: 87–96.
Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P . Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol 2005; 236: 6–16.
Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L et al. CD molecules 2005: human cell differentiation molecules. Blood 2005; 106: 3123–3126.
Ise T, Kreitman RJ, Pastan I, Nagata S . Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 2006; 44: 594–602.
Hooper NM, Karran EH, Turner AJ . Membrane protein secretases. Biochem J 1997; 321: 265–279.
Solberg H . Establishment and use of reference values. In: Buritis C, Ashwood E, Bruns D (eds) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St Louis: Saunders, 2006, 425–448.
Linnet K . Nonparametric estimation of reference intervals by simple and bootstrap-based procedures. Clin Chem 2000; 46: 867–869.
Helsel DR . Nondetects and Data Analysis. John Wiley & Sons: NJ, 2005, 1–268.
Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W et al. Flow cytmetric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom 2005; 67: 6–12.
Wierda WG, Kipps TJ, Keating MJ . Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 6325–6332.
Ghielmini M, Schmitz SFH, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss group for clinical cancer research (SAKK). J Clin Oncol 2005; 23: 705–711.
Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A et al. Cell membrane-specific epitopes on CD30: potentially superior targets for immunotherapy. Proc Natl Acad Sci USA 2005; 102: 7946–7951.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193–207.
Lu P . Staging and classification of lymphoma. Semin Nucl Med 2005; 35: 160–164.
Acknowledgements
This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ise, T., Nagata, S., Kreitman, R. et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21, 169–174 (2007). https://doi.org/10.1038/sj.leu.2404445
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404445
Keywords
This article is cited by
-
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
Nature Communications (2023)
-
Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma
Molecular Biology Reports (2023)
-
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Blood Cancer Journal (2019)
-
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates
BioDrugs (2016)
-
Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia
Cancer Immunology, Immunotherapy (2009)